Breast Cancer Risk with Menopausal Hormone Use Jackie Bouillon Advisor: Dr. Robert Hadley Spring 2007.

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
 Heart disease is women’s No. 1 killer  Stroke is women’s No. 3 killer.
Breast Cancer Tumor Board Chair Harold Burstein, MD, PhD Faculty Jennifer Bellon, MD Mehra Golshan, MD.
First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.
IS HRT SAFE? Rosol Hamid Consultant O&G. NO What is safe? Driving Swimming Crossing the street Cycling Riding a motor bike Parachute jumping Flying.
Obesity and Cancer: The Link. The Panel’s Recommendation.
The Affect Common Chemicals May Have on Women’s Hormone Therapy Presented By: Sean Snowden.
Hormone Replacement Therapy
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs)
Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR.
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Statistics: Unlocking the Power of Data Lock 5 Inference for Proportions STAT 250 Dr. Kari Lock Morgan Chapter 6.1, 6.2, 6.3, 6.7, 6.8, 6.9 Formulas for.
BREAST CANCER GROUP 6 :  Nuraini Ikqtiarzune Haryono( )  Tri Wahyu Ningsih ( )  Rani Yuswandaru ( )  Anita Rheza Fitriana Putri( )
2 years later, she noticed multiple cm
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
Postmenopausal Hormone Therapy And The Risk of Breast Cancer A Contrary Thought Leon Speroff, M.D.
Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.
Suggested guidelines for appropriate patient selection for patients undergoing Accelerated Partial Breast Irradiation at DMC. Tonya Echols Cole, MD.
AJCC Staging Moments AJCC TNM Staging 7th Edition Breast Case #1 Contributors: Stephen B. Edge, MD Roswell Park Cancer Institute, Buffalo, New York David.
Comparing the Positive Effect of Vitamin E and Flouxetine in the Treatment of Hot Flashes in Breast Cancer Patients. Comparing the Positive Effect of.
Session Fertility and Pregnancy FL-BBM Specific questions Risk of premature ovarian failure Ability to become pregnant Safety of pregnancy.
ER and PR Test Estrogen and Progesterone receptor status tests will show whether or not one or both of these hormones fuel the tumor Cancer that is hormone-sensitive.
OVARIAN CANCER RISK FACTORS Studies have found the following risk factors for ovarian cancer:  Family history of cancer: Women who have a mother, daughter,
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
MacLennan Selected Risks and Benefits after 5 Years of combined estrogen and progestogen HRT for all women aged (WHI Study, 2002) OESTROGEN WITH.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year.
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Breast Cancer in the Women’s Health Initiative Trial of Estrogen Plus Progestin For the WHI Investigators Rowan T Chlebowski, MD., Ph.D.
Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
MENAPOUSE. Natural Surgical premature RETROSPECTIVE Cessation of menstruation for 12 months In the absence of other physiological or psychological.
Menopausal Hormone Replacement Professor Gordana Prelevic, MD, DSc, FRCP Consultant Endocrinologist Royal Free Hampstead NHS Trust Whittington Health.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Reduced Lung Cancer Mortality Risk Among Breast Cancer Patients Treated With Anti- Estrogens Rapiti E et al. SABCS 2009;Abstract 35.
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.
Menopause Case Studies Interprofessional version
Finding Answers Online Comprehensiveness and accuracy in online information about breast cancer Kim Walsh-Childers, PhD Heather M. Edwards, MA University.
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
Tumor Marker Phenotype Concordance in Second Primary Breast Cancer Monica Brown, MPH, PhD California Cancer Registry Mary Paré, RN, BS Sutter Cancer Center,
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
By: Anthony, Sophia, Jessica, Terrance, and Sierra.
Menopause Take good care of our ladies!. What is Menopause? Menopause is a normal part of life, just like puberty. 9 月是全国妇女更年期认 知月 (National Menopause.
HORMONE REPLACEMENT THERAPY (HRT) Evidence-based Guidelines Dr Mahdy El- Mazzahy Damietta general Hospital 7 th International Annual Congress “Alexandria”
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Bacon and cancer Oct 25, 2015: World Health Organization Says Processed Meat Causes Cancer So we must stop eating processed meat, such as bacon or sausages?
Breast Cancer Treatment. Treatment 2 aspects 1. Treatment of the breast itself: “Local Treatment” 2. Treatment of the whole body = “Systemic treatment”
TMIST A Breast Cancer Screening Trial
Slamon D et al. SABCS 2009;Abstract 62.
Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.
Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,
Prognostic significance of tumor subtypes in male breast cancer:
Surgical Management of the Breast in Breast Cancer
Mostafa AL Turk Tatiana Hawat
Breast Health Katherine B. Lee, MD, FACP April 26, 2018.
Tailoring Statin Therapy in Women
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Hormone Replacement Therapy (HRT)
Breast Cancer.
Stamatia Destounis, MD, FACR, FSBI, FAIUM
Badwe RA et al. SABCS 2009;Abstract 72.
20-Year Risks of Breast-Cancer Recurrence
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Presentation transcript:

Breast Cancer Risk with Menopausal Hormone Use Jackie Bouillon Advisor: Dr. Robert Hadley Spring 2007

The HRT Controversy HRT was standard of therapy for menopausal symptoms for years HRT was standard of therapy for menopausal symptoms for years In early 2000’s positive view of HRT was changed with the results of WHI and HERS studies In early 2000’s positive view of HRT was changed with the results of WHI and HERS studies Showed association between HRT and increased risk for breast cancer, heart attack, stroke Showed association between HRT and increased risk for breast cancer, heart attack, stroke

Summary of HRT and Factors Associated with Breast Cancer Factors leading to worse prognosis Factors leading to worse prognosis Adiposity Adiposity Smaller body size and HRT use Smaller body size and HRT use Long term unopposed estrogen use (>15 yrs) Long term unopposed estrogen use (>15 yrs) Combined estrogen- progesterone regimens Combined estrogen- progesterone regimens Positive hormone tumor status (ER+/PR+) Positive hormone tumor status (ER+/PR+) Higher tumor grade Higher tumor grade Factors that do not lead to worse prognosis HRT use if overweight (no additional increased risk) Short-term unopposed estrogen use (<15 yrs) Negative hormone receptor tumor status (ER+/PR- or ER-/PR-)

HRT After Breast Cancer What about HRT for women with a history of breast cancer? What about HRT for women with a history of breast cancer? Very controversial issue Very controversial issue Typically HRT is avoided by women with prior breast cancer diagnosis for fear of recurrence Typically HRT is avoided by women with prior breast cancer diagnosis for fear of recurrence Most observational studies suggest that HRT does NOT increase breast cancer recurrence and mortality in women with a prior diagnosis Most observational studies suggest that HRT does NOT increase breast cancer recurrence and mortality in women with a prior diagnosis

HRT After Breast Cancer First 2 randomized controlled trials were stopped prematurely after showing an increase in recurrence with HRT use First 2 randomized controlled trials were stopped prematurely after showing an increase in recurrence with HRT use HABITS Trial: rate of recurrence significantly higher with HRT use HABITS Trial: rate of recurrence significantly higher with HRT use Stockholm Trial: no associated increase in recurrence with HRT use Stockholm Trial: no associated increase in recurrence with HRT use

Why the Disparity in the Results? HABITS Trial HABITS Trial Participants had higher grade lymph node involvement Participants had higher grade lymph node involvement Majority of women used combined HRT; small percentage used unopposed estrogen Majority of women used combined HRT; small percentage used unopposed estrogen Stockholm Trial Participants had lower grade lymph node involvement Majority of women used unopposed estrogen or combined in which progesterone was taken for short intervals

Conclusions More clinical trials needed before can make conclusions about HRT after breast cancer More clinical trials needed before can make conclusions about HRT after breast cancer Providers need to be aware of the factors associated with increased breast cancer risk Providers need to be aware of the factors associated with increased breast cancer risk Providers need to work with each patient individually to assess her need for HRT and risk factors to determine if HRT is appropriate Providers need to work with each patient individually to assess her need for HRT and risk factors to determine if HRT is appropriate